Atriva Therapeutics GmbH Employee Directory
Biotechnology ResearchBavaria, Germany2-10 Employees
Atriva Therapeutics is a clinical-stage biotechnology company focused on antiviral therapies for severe diseases driven by RNA viruses, including influenza and COVID-19. It pursues host-targeting strategies intended to limit viral replication while modulating the body's immune response, with the aim of reducing the chance of viral resistance and improving pandemic preparedness. The lead candidate, ATR-002 (zapnometinib), is a host-targeting agent designed to disrupt viral replication and influence immune pathways. Founded in 2015 in Tübingen by leading scientists and industry experts, the company is based in Planegg, Bavaria, with operations in Tübingen, Frankfurt, and Martinsried near Munich. In September 2023, Biocure Technology Inc. announced plans to acquire Atriva Therapeutics in a reverse-takeover arrangement.